Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PCV13 Immunogenicity in Asplenic Adults with Beta-thalassemia Major
NCT01846923Phase 4Unknown
- Sponsor
- Aghia Sophia Children's Hospital of Athens
- Start
- Oct 2010
- Primary completion
- Feb 2012
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Prevnar 13 in pneumococcal infection, sponsored by Aghia Sophia Children's Hospital of Athens. Primary endpoints: Immunoglobulin G (IgG) B memory cell response at 1 month and Immunoglobulin M (IgM) B memory cell response at 1 month. Status: unknown.
02
Drugs
Prevnar 13
03
Conditions
pneumococcal infection
Beyond the preview
Go deeper on NCT01846923.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01846923.